Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRY-box transcription factor 15 is a member of the SOX (SRY-related HMG-box) family of transcription factors, which play crucial roles in embryonic development and cell fate determination[1][3][5]. The protein functions as a transcriptional regulator by binding specific DNA sequences, sometimes in complex with other proteins, and acting as either an activator or repressor depending on the context[3]. SOX15 is implicated in several biological processes, including suppression of tumor cell proliferation (notably in pancreatic and prostate cancer), regulation of muscle differentiation via downregulation of muscle-specific genes, and skeletal muscle regeneration[3][4][8]. Diseases associated with this gene include various developmental disorders and types of cancer, with evidence supporting its role as a tumor suppressor by inhibiting pathways such as Wnt/β-catenin signaling[3][4]. No drugs are currently known to target SOX15 directly, and it is not recognized as a therapeutic target or biomarker in clinical practice[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRY-box transcription factor 15 (SOX15).